Ghent University Academic Bibliography

Show Sort by

Your filters: cql: parent exact "CLINICAL LYMPHOMA MYELOMA & LEUKEMIA"

Add to list
- Conference Paper
- C3
Epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma : updated EPCORE NHL-2 data

Lorenzo Falchi, Michael Roost Clausen, Fritz Offner (UGent) , Sven de Vos, Joshua Brody, Kim M. Linton, SYLVIA SNAUWAERT (UGent) , Raul Cordoba, Jun Wu, Irina Bykhovski, et al.

(2023) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 23(Supplement 1). p.S431-S432
Add to list
- Conference Paper
- C3
Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) : analysis of patient and disease-related factors associated with responses

Simon Harrison, Caroline Hasselbalch Riley, Salomon Manier, Sung-Soo Yoon, Antonio Pinto, Titouan Cazaubiel, Anna Guidetti, Rakesh Popat, Cyrille Touzeau, Enrique Ocio, et al.

(2023) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 23(Supplement 2). p.S3-S4
Add to list
- Conference Paper
- C3
Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

Simon Harrison, Caroline Hasselbalch Riley, Salomon Manier, Sung-Soo Yoon, Antonio Pinto, Titouan Cazaubiel, Anna Guidetti, Rakesh Popat, Cyrille Touzeau, Enrique Ocio, et al.

(2023) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 23(Supplement 2). p.S3-S3
Add to list
- Conference Paper
- C3
ELARA trial update : long-term clinical outcomes and correlative efficacy analyses of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (R/R FL)

Nathan Fowler, Martin Dreyling, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio Chavez, Emmanuel Bachy, et al.

(2023) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 23(Supplement 1). p.S534-S535
Add to list
- Journal Article
- A1
- open access
Recommendations for management of secondary antibody deficiency in multiple myeloma

Sergio Giralt, Stephen Jolles, Tessa Kerre (UGent) , Hillard M. Lazarus, S. Shahzad Mustafa, Genovefa A. Papanicolaou, Roberto Ria, Donald C. Vinh and John R. Wingard

(2023) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 23(10). p.719-732
Add to list
- Conference Paper
- C3
Phase 2 CARTITUDE-2 study (cohort B) : updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy

Mounzer Agha, Niels W. C. J. van de Donk, Adam D. Cohen, Yael C. Cohen, Sebastien Anguille, Tessa Kerre (UGent) , Wilfried Roeloffzen, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, et al.

(2022) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 22(Supplement 2). p.S408-S409
Add to list
- Journal Article
- A1
Comparison of the effectiveness and safety of the oral selective inhibitor of nuclear export, selinexor, in diffuse large B cell lymphoma subtypes

Rene-Olivier Casasnovas, George Follows, Josee M. Zijlstra, Joost S. P. Vermaat, Nagesh Kalakonda, Sylvain Choquet, Eric Van den Neste, Brian Hill, Catherine Thieblemont, Federica Cavallo, et al.

(2022) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 22(1). p.24-33
Add to list
- Journal Article
- A1
Effect of prior therapy and disease refractoriness on the efficacy and safety of oral selinexor in patients with diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis of the SADAL study

Michael Schuster, Josee Zijlstra, Rene-Olivier Casasnovas, Joost S. P. Vermaat, Nagesh Kalakonda, Andre Goy, Sylvain Choquet, Eric Van Den Neste, Brian Hill, Catherine Thieblemont, et al.

(2022) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 22(7). p.483-494
Add to list
- Conference Paper
- C3
Compass : a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients

Michel Delforge, Jolien Raddoux, Cindy Kenis, Anneleen Vanhellemont, Philippe Mineur, Ellen Hoornaert, Ka Lung Wu, Jo Caers, Koen Van Eygen, Alain Kentos, et al.

(2021) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 21(Supplement 2). p.S124-S124
Add to list
- Conference Paper
- C3
Long-term follow-up, up to 7 years, in the RESONATE-2 study of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL)

Jan Burger, Paul Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Peter Hillmen, Steve Coutre, Stephen Devereux, Sebastian Grosicki, et al.

(2021) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 21(Supplement 1). p.S316-S316
Add to list
- Conference Paper
- C3
Glofitamab step-up dosing (SUD) : updated efficacy data show high complete response rates in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (Pts)

Carmelo Carlo-Stella, Cyrus Khan, Martin Hutchings, Fritz Offner (UGent) , Franck Morschhauser, Emmanuel Bachy, Michael Crump, Anna Sureda, Gloria Iacoboni, Corinne Haioun, et al.

(2021) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 21(Supplement 1). p.S394-S394
Add to list
- Journal Article
- A1
- open access
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma

Yael C. Cohen, Albert Oriol, Ka Lung Wu, Noa Lavi, Philip Vlummens (UGent) , Carolyn Jackson, Wendy Garvin, Robin Carson, Wendy Crist, Jiayu Fu, et al.

(2021) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 21(1). p.46-+
Add to list
- Conference Paper
- C3
Ixazomib plus lenalidomide-dexamethasone (IRd) vs. placebo-Rd for newly diagnosed multiple myeloma (NDMM) patients not eligible for autologous stem cell transplant : the double-blind, placebo-controlled, phase 3 TOURMALINE-MM2 trial

Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Michel Attal, Fritz Offner (UGent) , Darrell J. White, Lionel Karlin, Lotfi Benboubker, Sophie Rigaudeau, Philippe Rodon, et al.

(2020) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 20(Supplement 1). p.S307-S308
Add to list
- Conference Paper
- C3
Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma : ICARIA-MM high-risk cytogenetics subgroup analysis

Simon J. Harrison, Paul G. Richardson, Adrian Alegre, David Simpson, Ming Chung Wang, Andrew Spencer, Sossana Delimpasi, Cyrille Hulin, Kazutaka Sunami, Thierry Facon, et al.

(2019) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 19(10). p.E33-E33
Add to list
- Conference Paper
- C3
Five-year follow-up after ibrutinib therapy for first-line treatment of chronic lymphocytic leukemia

Jan Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Steven E. Coutre, Stephen Devereux, et al.

(2019) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 19. p.S274-S274
Add to list
- Conference Paper
- C3
Effect of dose modifications on response to duvelisib in patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO trial

Ian Flinn, Marco Montillo, Arpad Illes, Gabriel Etienne, Julio Delgado, Bryone Kuss, Constantine Tam, Fritz Offner (UGent) , Francesc Bosch, Matthew Davids, et al.

(2019) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 19(Suppl 1). p.S273-S274
Add to list
- Conference Paper
- C3
Characterization of duvelisib in patients with refractory marginal zone lymphoma : data from the phase 2 DYNAMO trial

Eric Jacobsen, Juraj Duras, Kirit Ardeshna, Mohamad Cherry, Fritz Offner (UGent) , Jiri Mayer, Fontanet Bijou, Monica Tani, Gerardo Musuraca, Michele Merli, et al.

(2019) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 19. p.S312-S313
Add to list
- Conference Paper
- C3
A phase 2b study of selinexor in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Nagesh Kalakonda, Federica Cavallo, George Follows, Andre Goy, Joost S. P. Vermaat, Olivier Casasnovas, Orly Lavee, Marie Maerevoet, Josee Zijlstra, Sameer Bakhshi, et al.

(2019) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 19. p.S248-S249
Add to list
- Journal Article
- A1
VANTAGE 095: an international, multicenter, open-label study of vorinostat (MK-0683) in combination with bortezomib in patients with relapsed and refractory multiple myeloma

David S Siegel, Meletios Dimopoulos, Sundar Jagannath, Hartmut Goldschmidt, Simon Durrant, Jonathan L Kaufman, Xavier Leleu, Arnon Nagler, Fritz Offner (UGent) , Thorsten Graef, et al.

(2016) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 16(6). p.329-334
Add to list
- Journal Article
- A1
Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens

Pieternella Lugtenburg, Antonio Salar Silvestre, Francesca G Rossi, Lucien Noens (UGent) , Wanda Krall, Kate Bendall, Zsolt Szabo and Ulrich Jaeger

(2012) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 12(5). p.297-305

Academic Bibliography

Epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma : updated EPCORE NHL-2 data

Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) : analysis of patient and disease-related factors associated with responses

Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

ELARA trial update : long-term clinical outcomes and correlative efficacy analyses of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (R/R FL)

Recommendations for management of secondary antibody deficiency in multiple myeloma

Phase 2 CARTITUDE-2 study (cohort B) : updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy

Comparison of the effectiveness and safety of the oral selective inhibitor of nuclear export, selinexor, in diffuse large B cell lymphoma subtypes

Effect of prior therapy and disease refractoriness on the efficacy and safety of oral selinexor in patients with diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis of the SADAL study

Compass : a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients

Long-term follow-up, up to 7 years, in the RESONATE-2 study of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL)

Glofitamab step-up dosing (SUD) : updated efficacy data show high complete response rates in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (Pts)

Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma

Ixazomib plus lenalidomide-dexamethasone (IRd) vs. placebo-Rd for newly diagnosed multiple myeloma (NDMM) patients not eligible for autologous stem cell transplant : the double-blind, placebo-controlled, phase 3 TOURMALINE-MM2 trial

Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma : ICARIA-MM high-risk cytogenetics subgroup analysis

Five-year follow-up after ibrutinib therapy for first-line treatment of chronic lymphocytic leukemia

Effect of dose modifications on response to duvelisib in patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO trial

Characterization of duvelisib in patients with refractory marginal zone lymphoma : data from the phase 2 DYNAMO trial

A phase 2b study of selinexor in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

VANTAGE 095: an international, multicenter, open-label study of vorinostat (MK-0683) in combination with bortezomib in patients with relapsed and refractory multiple myeloma

Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens

Contents

Support

Contact